ATE298790T1 - Phosphatase oder ein entsprechendes derivat enthaltene pharmazeutische zusammensetzung - Google Patents

Phosphatase oder ein entsprechendes derivat enthaltene pharmazeutische zusammensetzung

Info

Publication number
ATE298790T1
ATE298790T1 AT94927860T AT94927860T ATE298790T1 AT E298790 T1 ATE298790 T1 AT E298790T1 AT 94927860 T AT94927860 T AT 94927860T AT 94927860 T AT94927860 T AT 94927860T AT E298790 T1 ATE298790 T1 AT E298790T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
pharmaceutical composition
composition containing
endotoxin
relates
Prior art date
Application number
AT94927860T
Other languages
English (en)
Inventor
Klaas Poelstra
Machiel Josephus Hardonk
Winston Willem Bakker
Dirk Klaas Fokke Meijer
Original Assignee
Pharmaaware Ip B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaaware Ip B V filed Critical Pharmaaware Ip B V
Application granted granted Critical
Publication of ATE298790T1 publication Critical patent/ATE298790T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
AT94927860T 1993-08-13 1994-08-10 Phosphatase oder ein entsprechendes derivat enthaltene pharmazeutische zusammensetzung ATE298790T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL1993/000171 WO1995005455A1 (en) 1993-08-13 1993-08-13 Pharmaceutical composition comprising phosphatase or a derivative thereof
PCT/NL1994/000189 WO1995005456A1 (en) 1993-08-13 1994-08-10 Pharmaceutical composition comprising phosphatase or a derivative thereof

Publications (1)

Publication Number Publication Date
ATE298790T1 true ATE298790T1 (de) 2005-07-15

Family

ID=19861990

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927860T ATE298790T1 (de) 1993-08-13 1994-08-10 Phosphatase oder ein entsprechendes derivat enthaltene pharmazeutische zusammensetzung

Country Status (10)

Country Link
US (1) US6290952B1 (de)
EP (1) EP0721501B1 (de)
JP (1) JP3835811B2 (de)
AT (1) ATE298790T1 (de)
AU (3) AU4835693A (de)
DE (1) DE69434414T2 (de)
DK (1) DK0721501T3 (de)
ES (1) ES2244956T3 (de)
PT (1) PT721501E (de)
WO (2) WO1995005455A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100198176B1 (ko) * 1995-05-25 1999-06-15 추후 보충 엔도톡신 혈증 및 그것에 의해 유발되는 다장기 부전증의 치료약
JP2002533679A (ja) * 1998-12-21 2002-10-08 フアーマアウエア・アイピー・ベー・ブイ アルカリホスファターゼのｌｐｓ−結合部分を使用する敗血症の診断
US7011965B2 (en) * 2001-03-09 2006-03-14 Regents Of The University Of Minnesota Compositions and methods for stimulating wound healing and fibroblast proliferation
US7888372B2 (en) * 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
US20040052851A1 (en) * 2002-09-16 2004-03-18 Graff Allan H. Modified release oral dosage form
AU2003298036A1 (en) * 2002-12-12 2004-07-09 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
US7048914B2 (en) * 2002-12-12 2006-05-23 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
US7374754B2 (en) * 2003-09-02 2008-05-20 Essential Skincare, Llc Use of placental alkaline phosphatase to promote skin cell proliferation
US20110142817A1 (en) * 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
US8574863B2 (en) * 2004-02-04 2013-11-05 Pharmaaware Sepsis B.V. Alkaline phosphatase for treating an inflammatory disease of the gastro-intestinal tract
ES2365023T3 (es) * 2004-04-21 2011-09-20 Enobia Pharma Inc. Conjugados de administración ósea y método de uso de los mismos para dirigir proteínas a hueso.
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
EP1973561B1 (de) * 2005-12-15 2011-02-09 Chemgen Corporation Enzyme zur reduzierung von immunologischem stress
EP1965830B1 (de) * 2005-12-28 2014-05-14 Zoltan Laboratories Llc Verwendung von alkalischer phosphatase zur erhaltung von gesunder gewebemasse bei säugetieren
EP1985697A1 (de) * 2007-04-27 2008-10-29 AM-Pharma B.V. Modifizierte Phosphatasen
ES2421717T3 (es) 2008-02-29 2013-09-05 Alloksys Life Science B V Fosfatasa alcalina para aumentar la actividad del sistema inmune en un mamífero con riesgo de enfermedades inflamatorias
EP2334306B1 (de) * 2008-08-29 2014-04-02 The General Hospital Corporation Verfahren zur modulation der magen-darm-flora mit alkalischer phosphatase
EP2533802B1 (de) * 2010-02-12 2015-08-19 The General Hospital Corporation Verfahren zur reduzierung oder hemmung von mit einer bakteriellen infektion verbundenen toxischen wirkungen mithilfe von alkaliphosphatase
EA201291138A1 (ru) 2010-04-30 2013-05-30 Алексион Фарма Интернэшнл Сарл Способы, композиции и наборы для лечения нарушений, связанных с минерализацией матрикса
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
EP2620162A1 (de) 2012-01-27 2013-07-31 Life Science Inkubator Enzym-Polymer-Konjugat zur Endotoxin-Detoxifikation
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
HUE039784T2 (hu) 2014-01-24 2019-02-28 Am Pharma Bv Kiméra alkalikus foszfatáz-szerû proteinek
PL3097188T3 (pl) 2014-01-24 2018-11-30 Am-Pharma B.V. Przetwarzanie końcowe fosfatazy alkalicznej
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (de) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017173413A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
EP3464573B1 (de) 2016-06-06 2026-03-04 Alexion Pharmaceuticals, Inc. Auswirkungen von metallen auf die herstellung von alkalischen phosphatasen
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
WO2018175413A1 (en) 2017-03-21 2018-09-27 Synthetic Biologics, Inc. Alkaline phosphatase formulations
KR20240158374A (ko) 2017-03-31 2024-11-04 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
WO2019139891A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
CA3094173A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EP4275761A3 (de) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkalische phosphatasemittel zur behandlung von bestrahlungsstörungen
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
JP7820148B2 (ja) 2018-08-10 2026-02-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
CA3130651A1 (en) * 2019-03-06 2020-09-10 Gambro Lundia Ab Blood treatment device comprising alkaline phosphatase
JP7660523B2 (ja) 2019-05-06 2025-04-11 セリバ・バイオロジクス・インコーポレイテッド アルカリリン酸塩に基づいた癌治療
GB2599573A (en) 2019-05-31 2022-04-06 Rhogen Biotech Llc Compositions and methods for detoxifying bacterial endotoxins
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US11103628B1 (en) * 2020-04-29 2021-08-31 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide
US10881781B1 (en) 2020-04-29 2021-01-05 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166766A (en) * 1976-08-09 1979-09-04 Wisconsin Alumni Research Foundation Method for quantitative assay of alkaline phosphatase isoenzymes in serum
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IL58421A (en) * 1979-10-09 1984-01-31 Yeda Res & Dev Production of(2'-5')oligoisoadenylate and pharmaceutical compositions containing it
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4409332A (en) * 1982-01-12 1983-10-11 Jefferies Steven R Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
US4720458A (en) * 1983-10-19 1988-01-19 Sullivan Cornelius W Heat sensitive bacterial alkaline phosphatase
US4782016A (en) * 1985-01-18 1988-11-01 Eastman Kodak Company Analytical element and method for determination of theophylline by enzyme inhibition
US4861597A (en) * 1986-05-20 1989-08-29 Wako Pure Chemical Industries, Ltd. Novel functionallized liposomes and a process for production thereof
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4873035A (en) * 1987-11-25 1989-10-10 Abbott Laboratories Preparation of sized populations of liposomes
US5017501A (en) * 1987-11-25 1991-05-21 Abbott Laboratories Preparation of uniformly sized liposomes encapsulating an aqueous liquid
GB8822738D0 (en) * 1988-09-28 1988-11-02 Medisense Inc Theophylline assay
ES2106737T3 (es) * 1990-02-07 1997-11-16 Abbott Lab Enzimas de fosfatasa alcalina con actividad especifica mejorada para uso en reactivos indicadores.
ATE119034T1 (de) * 1990-04-18 1995-03-15 Takeda Chemical Industries Ltd Liposomenzusammensetzung.
NL9100434A (nl) * 1991-03-11 1992-10-01 Rijksuniversiteit Farmaceutische preparaten voor de bestrijding van virale infecties en immuundeficientieziekten, de bereiding en toepassing daarvan.
JPH06508780A (ja) * 1991-07-11 1994-10-06 ビーティージー・インターナショナル・リミテッド 移植片材料
US5248590A (en) * 1991-07-22 1993-09-28 Becton, Dickinson And Company Surface modified liposomes
US5413924A (en) * 1992-02-13 1995-05-09 Kosak; Kenneth M. Preparation of wax beads containing a reagent for release by heating

Also Published As

Publication number Publication date
ES2244956T3 (es) 2005-12-16
AU7710194A (en) 1995-03-14
US6290952B1 (en) 2001-09-18
DK0721501T3 (da) 2005-08-29
PT721501E (pt) 2005-11-30
EP0721501B1 (de) 2005-06-29
JPH09502342A (ja) 1997-03-11
DE69434414D1 (de) 2005-08-04
AU1424399A (en) 1999-04-01
WO1995005456A1 (en) 1995-02-23
JP3835811B2 (ja) 2006-10-18
EP0721501A1 (de) 1996-07-17
AU698331B2 (en) 1998-10-29
DE69434414T2 (de) 2006-05-18
WO1995005455A1 (en) 1995-02-23
AU4835693A (en) 1995-03-14

Similar Documents

Publication Publication Date Title
ATE298790T1 (de) Phosphatase oder ein entsprechendes derivat enthaltene pharmazeutische zusammensetzung
DE69434431D1 (de) Methoden zur behandlung von muskelerkrankungen und muskelstörungen
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
AU1998583A (en) Pharmaceutical compositions of mopidamol
ATE428430T1 (de) Therapeutische zusammensetzungen zur verwendung bei der prophylaxe oder behandlung von durchfall
UA48939C2 (uk) Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
PT100850A (pt) Composicoes farmaceuticas contendo uma mistura sinergica de um agente uricosurico, em especial,de probenecid, com um agente antagonista de aminoacidos excitantes, em especial,um derivado de quinoxalina substituido e sua utilizacao no tratamento de doencas neurodegenerativas
ZA943744B (en) Therapeutic substituted guanidines
BR9702200A (pt) Compostos bicíclicos-aromáticos composição farmacéutica composição cosmética e utilização de uma composição cosmética
DE3584775D1 (de) Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken.
DE59508366D1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
IL133172A0 (en) Diphosphonic acid salts for the treatment of osteoporosis
DE68919673D1 (de) Verfahren zur behandlung und vorbeugung des verlustes von knochenmasse.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
DK0585371T3 (da) Aromatiske oligomere forbindelser, som er anvendelige til at imitere bioaktive makromolekyler
MX9800801A (es) Proteina mp52 arg humana.
BR0213162A (pt) Métodos para prevenção e tratamento da perda óssea com compostos esteróides
ATE193450T1 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von knochenbrüchen
RU93044518A (ru) Способ коррекции состава лечебных грязей
NO305958B1 (no) Fosfonosulfonatforbindelse, farmasoeytisk preparat inneholdende denne og anvendelse
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
ATE315398T1 (de) Synergistische, gold und ein corticosteroid enthaltende zusammensetzungen.
TW224943B (en) The pharmaceutical composition for the stimulation of bone formation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0721501

Country of ref document: EP